Register
Forgot your password?

Different strategies of catheter ablation of atrialfibrillation for improving clinical outcomes

Authors: A.V. Kozlov, S.S. Durmanov

Company: Federal Center of Cardiovascular Surgery of the Ministry of Health of the Russian Federation, ulitsa Stasova, 6, Penza, 440071, Russian Federation

For correspondence:  Sign in or register.


DOI: https://doi.org/10.24022/1997-3187-2017-11-4-348-360

For citation: Kozlov A.V., Durmanov S.S. Different strategies of catheter ablation of atrial fibrillation for improving clinical outcomes. Kreativnaya Kardiologiya (Creative Cardiology). 2017; 11 (4): 348–60 (in Russ.). DOI: 10.24022/1997-3187-2017-11-4-348-360

Received / Accepted:  14.07.2017/11.08.2017

Keywords: atrial fibrillation radiofrequency ablation isolation of the pulmonary veins efficiency

Full text:  

 

Abstract

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Various strategies of radiofrequency ablation (RFA) are considered: segmental osteal ablation of the pulmonary veins, antral isolation, linear effects in the left atrium, ablation of complex fractionated atrial electrograms (CFAEs), ablation of the ganglionic plexuses, stepwise ablation, ablation of the “rotors” and focal impulses. Currently, antral isolation of pulmonary veins (PV) is considered to be the most advantageous strategy of AF ablation, as it allows to influence a greater number of mechanisms that cause and support arrhythmia. There are conflicting data, and currently the role of additional ablations in improving clinical outcomes remains controversial and requires further research. Recovery in isolated pulmonary veins is almost universal finding in patients undergoing repeated RFA of AF, although the connection between electrical reconnection and return of arrhythmia remains unclear. Several methods are considered to increase the probability of creating a permanent isolation of the mouths of PV: increasing the waiting time after acute isolation of PV and re-ablation of emerging “breakthroughs” of excitation, high-amplitude stimulation from the mapping catheter along the created line of injury and reablation of sites with preserved excitability, adenosine administration detection of concealed conduction, the use of ablative catheters with technology to control the force of contact with tissue to create a more resistant to myocardial lesion. Isolation of the mouths of PV is the only method with proven effectiveness in the interventional treatment of AF. At the moment there is no method that provides 100% permanent isolation of pulmonary veins after a single procedure.

References

  1. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001; 285 (18): 2370–5.

  2. Naccarelli G.V., Varker H., Lin J., Schulman K.L. Increasing prevalence of atrial fibrillation and flutter in the United States. Am. J. Cardiol. 2009; 104 (11): 1534–9.

  3. Lloyd-Jones D.M., Wang T.J., Leip E.P., Larson M.G., Levy D., Vasan R.S. et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004; 110 (9): 1042–6.

  4. Psaty B.M., Manolio T.A., Kuller L.H., Kronmal R.A., Cushman M., Fried L.P. et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997; 96 (7): 2455–61.

  5. Nucifora G., Schuijf J.D., van Werkhoven J.M. et al. Relationship between obstructive coronary artery disease and abnormal stress testing in patients with paroxysmal or persistent atrial fibrillation. Int. J. Cardiovasc. Imaging. 2011; 27: 777–81.

  6. Thrall G., Lane D., Carroll D., Lip G.Y. Quality of life in patients with atrial fibrillation: a systematic review. Am. J. Med. 2006; 119 (5): 448.

  7. Bockeria L.A., Revishvili A.Sh., Golitsyn S.P.,Egorov D.F., Popov S.V., Sulimov V.A. All-RussianScientific Society of Clinical Electrophysiology,Arrhythmology and Pacemakers Clinical recom-mendations for conducting electrophysiologicalstudies, catheter ablation and the use ofimplantable antiarrhythmic devices. 3th ed.Moscow: MAKS Press; 2013: 371 (in Russ.).

  8. Kerr C.R., Humphries K.H., Talajic M., Klein G.J., Connolly S.J., Green M. et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am. Heart J. 2005; 149 (3): 489–96.

  9. Steinberg J.S., Sadaniantz A., Kron J., Krahn A., Denny D.M., Daubert J. et al. Analysis of causespecific mortality in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation. 2004; 109 (16): 1973–80.

  10. Wazni O.M., Marrouche N.F., Martin D.O., Verma A., Bhargava M., Saliba W. et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005; 293 (21): 2634–40.

  11. Stabile G., Bertaglia E., Senatore G., De Simone A., Zoppo F., Donnici G. et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (catheter ablation for the cure of atrial fibrillation study). Eur. Heart J. 2006; 27 (2): 216–21.

  12. Pappone C., Augello G., Sala S., Gugliotta F., Vicedomini G., Gulletta S. et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF study. J. Am. Coll. Cardiol. 2006; 48 (11): 2340–7.

  13. Calkins H., Reynolds M.R., Spector P., Sondhi M., Xu Y., Martin A. et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ. Arrhythm. Electrophysiol. 2009; 2 (4): 349–61.

  14. Moreno J., Zamorano J.L. The CABANA trial. Eur. Heart J. 2014; 35: 1907–13.

  15. Jones D.G., Haldar S.K., Hussain W. et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J. Am. Coll. Cardiol. 2013; 61: 1894–903.

  16. Mont L., Bisbal F., Hernandez-Madrid A., Perez-Castellano N., Vinolas X., Arenal A. et al. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur. Heart J. 2014; 35: 501–7.

  17. Morillo C.A., Verma A., Connolly S.J., Kuck K.H., Nair G.M., Champagne J. et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014; 311: 692–700.

  18. Ganesan A.N., Shipp N.J., Brooks A.G., Kuklik P., Lau D.H., Lim H.S. et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J. Am. Heart Assoc. 2013; 2: e004549.

  19. Haissaguerre M., Jais P., Shah D.C., Takahashi A., Hocini M., Quiniou G. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 1998; 339 (10): 659–66.

  20. Haissaguerre M., Shah D.C., Jais P., Hocini M., Yamane T., Deisenhofer I. et al. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation. 2000; 102 (20): 2463–5.

  21. Pappone C., Rosanio S., Oreto G., Tocchi M., Gugliotta F., Vicedomini G. et al. Circumferential radiofrequency ablation of pulmonary vein ostia: a new anatomic approach for curing atrial fibrillation. Circulation. 2000; 102 (21): 2619–28.

  22. Lemola K., Chartier D., Yeh Y.H., Dubuc M., Cartier R., Armour A. et al. Pulmonary vein region ablation in experimental vagal atrial fibrillation. Role of pulmonary veins versus autonomic ganglia. Circulation. 2008; 117 (4): 470–7.

  23. Proietti R., Santangeli P., Di Biase L., Joza J., Bernier M.L., Wang Y. et al. Comparative effectiveness of wide antral versus ostial pulmonary vein isolation: a systematic review and meta-analysis. Circ. Arrhythm. Electrophysiol. 2014; 7 (1): 39–45.

  24. Malik A.K., Ching Ch.-K. Catheter ablation for atrial fibrillation: a review of the literature. PoSH. 2015; 24: 16–23.

  25. Verma A., Jiang C.Y., Betts T.R., Chen J., Deisenhofer I., Mantovan R. et al. STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N. Engl. J. Med. 2015; 372: 1812– 22.

  26. Zhang Z., Letsas K.P., Zhang N., Efremidis M., Xu G., Li G., Liu T. Linear ablation following pulmonary vein isolation in patients with atrial fibrillation: a meta-analysis. Pace. 2016; 39: 623–30.

  27. Rostock T., O’Neill M.D., Sanders P. et al. Characterization of conduction recovery across left atrial linear lesions in patients with paroxysmal and persistent atrial fibrillation. J. Cardiovasc. Electrophysiol. 2006; 17: 1106–11.

  28. Nademanee K., McKenzie J., Kosar E., Schwab M., Sunsaneewitayakul B., Vasavakul T. et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J. Am. Coll. Cardiol. 2004; 43 (11): 2044–53.

  29. Providencia R., Lambiase P.D., Srinivasan N., Ganesh Babu G., Bronis K., Ahsan S. et al. Is There Still a Role for Complex Fractionated Atrial Electrogram Ablation in Addition to Pulmonary Vein Isolation in Patients With Paroxysmal and Persistent Atrial Fibrillation? Circ. Arrhythm. Electrophysiol. 2015; 8: 1017– 29.

  30. Pappone C., Santinelli V., Manguso F., Vicedomini G., Gugliotta F., Augello G. et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. 2004; 109 (3): 327–34.

  31. Pokushalov E.A., Turov A.P., Shugaev P.L. et al.A new approach in the treatment of atrial fibrilla-tion: a catheter ablation of the ganglionic plexusesin the left atrium. Vestnik Aritmologii (Journal ofArrhythmology).2006; 45: 17–27 (in Russ.)

  32. Shabanov V.V., Romanov A.B., Turov A.N.,Elesin D.A., Stenin I.G., Yakubov A.A. et al. Five-year experience of using radiofrequency ablation ofthe left atrium ganglionic plexus in patients withparoxysmal atrial fibrillation Vestnik Aritmologii(Journal of Arrhythmology). 2010; 61: 5–10(in Russ.).

  33. Stenin I.G., Romanov A.B., Shabanov V.V.,Elesin D.A., Yakubov A.A., Losik D.V. Radiofrequency ablation of the left atrial ganglionicplexus in patients with chronic atrial fibrillation.Vestnik Aritmologii (Journal of Arrhythmology).2011; 65: 19–24 (in Russ.).

  34. Driessen A.H.G., Berger W.R., Krul S.P.J., van den Berg. N.W.E., Neefs J., Piersma F.R. et al. Ganglion Plexus Ablation in Advanced Atrial Fibrillation The AFACT Study. J. Am. Coll. Cardiol. 2016; 68 (11): 1155–65.

  35. Faustino M., Pizzi C., Agricola T., Xhyheri B., Maria C.G., Flacco M.E. et al. Stepwise ablation approach versus pulmonary vein isolation in patients with paroxysmal atrial fibrillation: Randomized controlled trial. Heart Rhythm. 2015; 12 (9): 1907–15.

  36. Vogler J., Willems S., Sultan A., Schreiber D., Lüker J., Servatius H. et al. Pulmonary vein isolation versus defragmentation the CHASE-AF clinical trial. J. Am. Coll. Cardiol. 2015; 66 (24): 2743–52.

  37. Vaquero M., Calvo D., Jalife J. Cardiac fibrillation: from ion channels to rotors in the human heart. Heart Rhythm. 2008; 5: 872–9.

  38. Narayan S.M., Krummen D.E., Shivkumar K., Clopton P., Rappel W.-J., Miller J.M. Treatment of atrial fibrillation by the ablation of localized sources CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. JACC. 2012; 60 (7): 628–36.

  39. Gianni C., Mohanty S., DiBiase L. et al. Acute and early outcomes of focal impulse and rotor modulation (FIRM)-guided rotors-only ablation in patients with nonparoxysmal atrial fibrillation. Heart Rhythm. 2016; 13: 830–5.

  40. Buch E., Share M., Tung R., Benharash P.,Sharma P., Shivkumar K. et al. Long-term clinical outcomes of focal impulse and rotor modulation for treatment of atrial fibrillation: A multicenter experience. Heart Rhythm. 2016; 13: 636–41.

  41. Andrew E. Darby recurrent atrial fibrillation after catheter ablation: considerations for repeat ablation and strategies to optimize success. JAFIB. 2016; 9 (1): 46–53.

  42. Nakamura K., Naito S., Kaseno K. et al. Optimal observation time after completion of circumferential pulmonary vein isolation for atrial fibrillation to prevent chronic pulmonary vein reconnections. Int. J. Cardiol. 2013; 168: 5300–10.

  43. Steven D., Sultan A., Reddy V., Luker J., Altenburg M., Hoffmann B. et al. Benefit of pulmonary vein isolation guided by loss of pace capture on the ablation line: results from a prospective 2-center randomized trial. J. Am. Coll. Cardiol. 2013; 62: 44–50.

  44. McLellan A.J.A., Kumar S., Smith C., Morton J.B., Kalman J.M., Kistler P.M. The role of adenosine following pulmonary vein isolation in patients undergoing catheter ablation for atrial fibrillation: a systematic review. J. Cardiovasc. Electrophysiol. 2013; 24 (7): 742–51.

  45. Ullah W., McLean A., Tayebjee M.H. et al. Randomized trial comparing pulmonary vein isolation using the SmartTouch catheter with or without real-time contact force data. Heart Rhythm. 2016; 13 (9): 1761–7.Б.

About Authors

  • Kozlov Aleksandr Viktorovich, Cardiologist, orcid.org/0000-0002-0529-0081;
  • Durmanov Sergey Semenovich, Cand. Med. Sc., Head of Department, orcid.org/0000-0002-4973-510X

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by